An experimental immunotherapy candidate targets toxic species of alpha-synuclein and was well tolerated in an ongoing, ...

Immatics (IMTX) has released an update. Immatics has reported promising updated Phase 1b clinical data for its ACTengine ...

Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits ...

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial ...

Boeing subsidiary Aurora Flight Sciences is working on a high-speed VTOL military aircraft as part of DARPA's Speed & Runway ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

In the Phase 1b dose expansion part of the study, heavily pretreated patients with metastatic melanoma were treated with IMA203. Data from the study showed a significant positive shift in median ...

Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last ...